Newly Diagnosed Glioblastoma Multiforme
3
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Granulocyte Colony Stimulating Factor Gcsf
Research Leaders
5 sponsors active, led by Massachusetts General Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
G-CSF After Chemo-radiation in Patients With Glioblastoma
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
Research Network
Common Treatments
- Granulocyte Colony Stimulating Factor Gcsf1
- Radiation Therapy Temozolomide1
- Msc11fcd1
- Lapatinibtemozolomideradiation1
Active Sponsors
- Massachusetts General Hospital1
- Novartis1
- GSK1
- CHA University1
- Jonsson Comprehensive Cancer Center1
Top Investigators
CHA University
University of California, Los Angeles
Massachusetts General Hospital
Related Conditions
- Glioblastoma Gbm2
- Mgmtmethylated Glioblastoma1